GenAI pilots are running, but governance is not keeping up. That gap is where enterprise risk accumulates.
GenAI Has Achieved Widespread Adoption. Execution Maturity Has Not.
Most pharma commercial and medical IT organizations report that AI adoption is underway. The problem is what sits beneath that headline:
- Underpowered data foundations: data and cloud foundations remain below the threshold needed to support scaled AI.
- Fragmented governance: despite strong self-reported compliance confidence, governance cadence varies widely, leaving organizations exposed to model drift, audit risk, and regulatory scrutiny.
- Limited focus on innovation: 67% of organizations allocate less than 25% of their digital budget to innovation, leaving the rest committed to run-the-business work.
The consequences are predictable: more pilots, limited industrialization, and growing exposure. Risks include rework when models drift, compliance issues when governance reviews miss cadence, and stalled transformation when the foundation cannot support the use-cases leadership is prioritizing.
About This Advisory Brief
Survey-based perspective on AI governance, data and cloud foundations, and value realization.
This advisory brief reflects TGaS Advisors’ analysis of the annual pharma Commercial and Medical IT (CMIT) landscape survey, conducted across a cross-section of pharmaceutical organizations. Findings are directionally strong and should be interpreted as a market signal rather than a statistical benchmark.
The brief covers seven focus areas: digital transformation maturity, AI adoption, investment patterns, barriers to digital expansion, operational ROI, future readiness, and leadership organization. For each, it translates survey findings into implications for enterprise executive teams and CIO/CDO-relevant actions.
This brief cuts through the noise by translating real-world CMIT data into clear decisions to accelerate execution over the next 12–36 months.
What You Will Learn
- Where pharma digital maturity actually stands across seven focus areas, based on peer survey data rather than self-reported progress.
- Why high compliance confidence can increase regulatory exposure when governance cadence is fragmented and inconsistent.
- Where AI investment is paying off today, including foundational automation and contract modeling, and where advanced tools remain early-stage.
- How to sequence the next 12 to 36 months: govern AI, prove value with funded proof points, then commit to data and cloud architecture.
- Seven executive decisions to move from pilot to scaled impact, each mapped to the specific challenge it addresses.
- An enterprise risk portfolio covering AI governance gaps, foundation deficits, talent concentration, measurement bias, and innovation starvation.
Complete the form to access the full advisory brief.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.